Group Dinner Meeting with Management in New York on December 2 hosted by Oppenheimer.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- Buy Rating for Aquestive Therapeutics Driven by Anaphylm’s FDA Approval Prospects and Market Potential
- Aquestive Therapeutics price target raised to $8 from $5 at Piper Sandler
- Aquestive Therapeutics Reports Q3 2025 Financial Results
- Aquestive Therapeutics’ Earnings Call: Optimism Amid Challenges
- Aquestive Therapeutics Advances Anaphylm Towards FDA Approval